Anavex Discloses FDA Pediatric Meeting and Two New Board Nominees in Proxy Fight
AVXL is trading near its 52-week low of $2.255 (8.2% above the low).
Summary
Anavex's latest proxy solicitation letter adds two new independent board nominees and reveals an FDA meeting on pediatric Rett Syndrome trial design, while sharply criticizing PVG's slate ahead of the September 24 vote.
Key Events · Corporate Governance and Compliance · AVXL
-
FDA Pediatric Meeting Disclosed
Anavex announced the FDA granted a meeting to discuss including pediatric participants in the Phase 3 study of blarcamesine for Rett Syndrome — a new regulatory development in the proxy fight.
-
Two New Board Nominees
Gautam Patel and Dr. Adrian Senderowicz are nominated as independent directors; if elected, half the board will have been refreshed since the start of 2026.
-
Attack on PVG Slate
The letter alleges PVG nominee Jason Kolbert has a close friendship with former CEO Christopher Missling and that nominee Patrick Adams settled a 2016 Colorado securities matter over undisclosed conflicts.
-
September 24 Vote
Stockholders are urged to vote the WHITE proxy card for all six Anavex nominees at the annual meeting on September 24, 2026.
Analysis · AVXL · Life Sciences
Nine days before the September 24 annual meeting, Anavex mailed a stockholder letter that adds two new independent board nominees — Gautam Patel and Dr. Adrian Senderowicz — and discloses that the FDA granted a meeting to discuss including pediatric participants in the Phase 3 Rett Syndrome study of blarcamesine. The letter also launches a detailed attack on PVG's slate, alleging nominee Jason Kolbert has a close friendship with former CEO Christopher Missling and that nominee Patrick Adams settled a 2016 Colorado securities matter over undisclosed conflicts. These are new facts in an already high-stakes proxy contest where PVG seeks to replace the entire board.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.2M. The 52-week trading range was $2.26 to $10.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.